Early Phase Clinical Trial About Therapeutic Biological Product Mix for Treating HPV

Running, not enrolling · Early Phase 1

Conditions studied: HPV Infection

In brief

Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients. 1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity. 2. Activate human HPV Antigen Presentation Reaction. 3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.

Key facts

Study ID

NCT06959563

Run by

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

People needed

20

Starts

2025-04-28

Expected to finish

2026-10-28

Last updated by the study team

2026-05-20

Who can join

Age: 24 and older, up to 64. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Cervical HPV Infection Patients
• Positive testing HPV by standard PCR assay
• HPV infection without symptoms
• No clinical signs indicative of oncology
• TB negative participant is negative IGRA blood test with TB antigens

You may not qualify if…

• Pregnant
• Thrombosis
• Bleeding
• Allergy
• TB positive participant is positive IGRA blood test with TB antigens
• Symptoms of HPV infection
• Clinical signs suggestive of other infection
• Symptoms suggestive of other infection
• Clinical signs indicative of oncology
• Evidence of critical illness

Where it is running

• Medicine Invention Design, Inc. — Rockville, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.